<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To study the clinical characteristics and the evolution of vena cava <z:mp ids='MP_0005048'>thrombosis</z:mp> (VCT) in <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD), as well as their association with other severe symptoms </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Among 121 BD, we selected those with VCT </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients fulfilled the diagnostic criteria of the international study group of <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Different clinical and paraclinical parameters were determined and compared with the remaining group of patients (not having VCT) with chi 2 test with Yates' correction </plain></SENT>
<SENT sid="4" pm="."><plain>Protein C, protein S and antithrombin III and anticardiolipin antibody (aCL) levels were measured in 9 patients; anti-beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies (a beta 2GPI) were determined in 3 patients </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Ten patients had a vena cava <z:mp ids='MP_0005048'>thrombosis</z:mp> (8.2%) </plain></SENT>
<SENT sid="6" pm="."><plain>They were <z:hpo ids='HP_0000001'>all</z:hpo> male with an average age of 35 years (range: 30-42) </plain></SENT>
<SENT sid="7" pm="."><plain>We had 3 cases of superior vena cava <z:mp ids='MP_0005048'>thrombosis</z:mp>, 6 cases of inferior VCT, and one case of both </plain></SENT>
<SENT sid="8" pm="."><plain>The average delay to diagnosis of the VCT from the date of the BD diagnosis was 4.5 years (range: 6 months-14 years), and in one case the <z:mp ids='MP_0005048'>thrombosis</z:mp> revealed the disease </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were clinically symptomatic and the installation of the symptoms were progressive and insidious in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="10" pm="."><plain>Six patients had <z:hpo ids='HP_0002639'>Budd-Chiari syndrome</z:hpo> and 4 had a <z:mp ids='MP_0010140'>phlebitis</z:mp> of a lower limb </plain></SENT>
<SENT sid="11" pm="."><plain>Among <z:hpo ids='HP_0000001'>all</z:hpo> the clinical characteristics studied, only neurological manifestations was significantly higher in patients with VCT (p = 0.001) </plain></SENT>
<SENT sid="12" pm="."><plain>Protein C, protein S and antithrombin III levels were <z:mpath ids='MPATH_458'>normal</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="13" pm="."><plain>One patients was positive for IgG aCL and no patient was positive for a beta 2GPI </plain></SENT>
<SENT sid="14" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> our patients were treated by anticoagulation therapy and high-dose <z:chebi fb="0" ids="8382">prednisone</z:chebi> combined with intravenous <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> in 5 cases </plain></SENT>
<SENT sid="15" pm="."><plain>One patient died due to <z:hpo ids='HP_0001399'>liver failure</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>The 9 others are clinically improved (6 cases) or stable (3 cases) after an average 2.5 year course </plain></SENT>
</text></document>